AIMSPRO® (Hyperimmune Caprine Sera, HICS) is a purified protein multi-peptide conjugate complex which is being developed exclusively by Daval International, to provide a unique biological treatment which targets several immune diseases by regulating and stabilising the immune system.
AIMSPRO® is an innovative treatment which takes effect through the introduction of a stabilised Corticotropin-releasing hormone (CRH). A lack of CRH is a common factor in patients suffering degenerative conditions such as MS, ALS and Alzheimer's, and also an issue as patients age.
There may be evidence to suggest a causal link between low CRH and aggressive disease phenotypes, and so research is being under taken into long term replacement.
AIMSPRO® development has focused on three key areas of treatment: Scleroderma, Amyotrophic Lateral Sclerosis (ALS) and Secondary Progressive Multiple Sclerosis (SPMS).
Phase II proof of concept trials have been carried out at the Royal Free Hospital, London, for the treatment of Secondary Progressive Multiple Sclerosis (SPMS) and the treatment of late-stage Scleroderma (SSc), both of which were double-blind and placebo-controlled.
Principal Investigators signed-off on both final trials and results have been submitted to Ethics Committees and the MHRA.
In 2012, the American College of Rheumatology (ACR) and the European League Against Rheumatism Meeting (EULAR) were presented with findings from the SSc clinical trial.
In March 2013, findings from ALS research and other pre-clinical trials were presented to the American Academy of Neurology Annual Meeting and another clinical study into the AIMSPRO® effect on ALS has also been completed.
In May of the same year, the Consortium of Multiple Sclerosis Centers (CMSC) and Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) were presented with analysis of findings into the effects of AIMSPRO® on patients with progressive multiple sclerosis.